Table 2.
Phenotypic resistance of Escherichia coli causing BSI in Vietnam
| Overall, n = 115 | ESBL+, n = 67 | ESBL−, n = 48 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | S | I | R | ||||||||||
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
| AM | 5 | 4.3 | 1 | 0.9 | 109 | 94.8 | 0 | – | 0 | – | 67 | 100.0 | 5 | 10.4 | 1 | 2.1 | 42 | 87.5 |
| AMC | 67 | 58.3 | 16 | 13.9 | 32 | 27.8 | 43 | 64.2 | 12 | 17.9 | 12 | 17.9 | 24 | 50.0 | 4 | 8.3 | 20 | 41.7 |
| TZP | 93 | 80.9 | 14 | 12.2 | 8 | 7.0 | 59 | 88.1 | 7 | 10.4 | 1 | 1.5 | 34 | 70.8 | 7 | 14.6 | 7 | 14.6 |
| CAZ | 62 | 53.9 | 1 | 0.9 | 52 | 45.2 | 31 | 46.3 | 1 | 1.5 | 35 | 52.2 | 31 | 64.6 | 0 | – | 17 | 35.4 |
| CTX | 34 | 29.6 | 0 | 0.0 | 81 | 70.4 | 0 | 0.0 | 0 | 0.0 | 67 | 100.0 | 34 | 70.8 | 0 | – | 14 | 29.2 |
| FEPa | 68 | 62.4 | 13 | 11.9 | 28 | 25.7 | 34 | 55.7 | 11 | 18.0 | 16 | 26.2 | 34 | 70.8 | 2 | 4.2 | 12 | 25.0 |
| ETP | 112 | 97.4 | 2 | 1.7 | 1 | 0.9 | 66 | 98.5 | 1 | 1.5 | 0 | – | 46 | 95.8 | 1 | 2.1 | 1 | 2.1 |
| IPM | 115 | 100.0 | 0 | – | 0 | – | 67 | 100.0 | 0 | – | 0 | – | 48 | 100.0 | 0 | – | 0 | – |
| MEM | 115 | 100.0 | 0 | – | 0 | – | 67 | 100.0 | 0 | – | 0 | – | 48 | 100.0 | 0 | – | 0 | – |
| AN | 113 | 98.3 | 1 | 0.9 | 1 | 0.9 | 67 | 100.0 | 0 | – | 0 | – | 46 | 95.8 | 1 | 2.1 | 1 | 2.1 |
| GM | 73 | 63.5 | 3 | 2.6 | 39 | 33.9 | 43 | 64.2 | 1 | 1.5 | 23 | 34.3 | 30 | 62.5 | 2 | 4.2 | 16 | 33.3 |
| CIP | 37 | 32.2 | 1 | 0.9 | 77 | 67.0 | 17 | 25.4 | 1 | 1.5 | 49 | 73.1 | 20 | 41.7 | 0 | – | 28 | 58.3 |
AMC: Amoxicillin/Clavulanic acid; TZP: Piperacillin/Tazobactam; ESBL: extended spectrum beta lactamase; CTX: Cefotaxime; CAZ: Ceftazidime; FEP: Cefepime; AN: Amikacin; CIP: Ciprofloxacin; S: susceptible; I: intermediate; R: resistant
amissing values for FEP susceptibility, n = 6 in ESBL-producers (ESBL+)